At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 20 enrolled
Drug / intervention
Placebo +1 moredrug
Likely dose
Oxytocin 24 IUfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Deciphering the Role of Oxytocin in Motivation: an fMRI Study
In Brief
A Phase 2 clinical trial evaluating Placebo and Oxytocin for Focus of Study: Neural Correlates of Oxytocin Administration. Completed, enrolled 20 participants across 1 site.
Detailed Summary
The proposed study will investigate the effects of intranasal oxytocin administration on neural activity associated with social and non-social motivation.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
CollaboratorsUniversity of Michigan
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartOct 2012
First PostedNov 2012
Primary CompletionSep 2013
Study CompletionOct 2015
TodayJul 2026
First PostedNov 6, 2012
Enrollment StartOct 1, 2012
Primary CompletionSep 1, 2013
Study CompletionOct 1, 2015
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 13.7 years ago
Interventions
Placebodrug
Placebo intranasal administration, 3 puffs per nostril delivered approximately 30 minutes prior to scanning session.
Oxytocindrug
Oxytocin intranasal administration, 24 IU, 3 puffs per nostril at 4 IU per puff delivered approximately 30 minutes prior to scanning session.